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Introduction: High flow nasal cannulas (HFNC) are an oxygen supply device that has become 
increasingly popular. This high flow therapy was initially utilized in the neonatal populations for 
treatment of conditions such as bronchiolitis and respiratory distress. The mechanism of 
treatment behind HFNC in these conditions relies upon the large amount of flow which produces 
continuous positive airway pressure (CPAP) against the airways. This pressure maintains the 
structural patency of the airway, allowing for continuous flow during inspiration and expiration. 
The small amount of CPAP generated by the HFNC assists in oxygenation and gas exchange by 
expanding the size of alveoli at end expiration and generating a greater surface area for diffusion 
across the alveolar capillary membrane. The purpose of this study was to determine if greater 
flows generated from the HFNC to a pediatric in vitro model would affect the mean airway 
pressure (MAP). Method: A pediatric in vitro model was utilized to simulate two spontaneous 
breathing patterns with the use of a Dual Adult Test and Training Lung (TTL) connected to a 
Hamilton-G5 ventilator. Positive pressure ventilation delivered to one side A of the Dual Adult 
TTL simulated a spontaneously breathing negative pressure model on the other side B of the 
Dual Adult TTL. The two sides of the Dual Adult TTL were connected via a wooden board and 
clamped to cause simultaneous movement of both lungs. HFNC delivered flow to side B through 
a fabricated airway. A pressure sensor placed between the MIL TTL and the fabricated airway 
and connected to an auxiliary pressure monitoring port on the Hamilton-G5 ventilator. Three 
different HFNC were used and tested at two various flows (10, 15, and 20 liters per minute 
(L/min)) and two different respiratory patterns (labored and unlabored). No other parameters 
were changed. Data Analysis: two-way analysis of variance (ANOVA), descriptive statistics, 
and post hoc Bonferroni were used for this study. SPSS 26.0 for Windows was used for all data 
analysis in this study Results: The average MAP produced by all three HFNC were increased at 
all flow rates. Greater flow rates up to 20 L/min created a greater amount of MAP, an average of 
2.34 cm H2O and 2.49 for unlabored and labored breathing pattern respectively at 20 L/min. The 
Hudson HFNC generated the greatest MAP of all three HFNC (3.81 cm H2O at 20 L/min, 
labored breathing pattern). Based on ANOVA analysis, increased flows through all devices were 
statistically significant based on a p value of 0.05. Conclusions: A significant difference in MAP 
was found between flow rates for all devices and simulated breathing patterns, devices for all 
flow rates and simulated breathing patterns, and both simulated breathing patterns for all devices 
and flow rates.  
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The high flow nasal cannula (HFNC) is an increasingly popular piece of equipment that 
provides a moderate-to-high amount of flow to patients through the nasal passage (Lodeserto, 
2018). The benefits of high flow therapy are twofold: to provide a small degree of pressure to the 
airway and parenchyma and to washout physiological dead space from the airway (Nishimura, 
2016; Spoletini et al., 2015; Spicuzza & Schisano, 2020) . The dead space washout helps a 
patient in multiple ways. First, we must present the conditions most affected by dead space, the 
increase in carbon dioxide (CO2) within the body known as hypercapnia, and the decrease in 
oxygen within the body known as hypoxia (Frat et al., 2015). Hypercapnia is an elevated amount 
of carbon dioxide (CO2) in a person’s body. CO2 is a normal byproduct of various metabolic 
processes that occur within the body. Normal levels of CO2 in the arteries (PaCO2) are 
maintained through excretion through the lungs, as the CO2 diffuses from the pulmonary 
capillaries through the alveolar capillary membrane and into the alveoli. The movement of gas 
into and out of the body completes the cycle of CO2 elimination. However, due to the anatomy of 
the airways and volumes of the lungs, each breath does not ventilate enough gas to completely 
clear the CO2 that resides within the airways. This causes the rebreathing of CO2 and increases 
the CO2 composition that fills the alveoli with each breath. In addition to occupying alveolar 
space that could be filled with oxygen used in oxygen diffusion, the CO2 gradient between the 
alveoli and alveolar capillaries is affected and can contribute to slower diffusion across the 
alveolar capillary membrane. This will lead to a slower rate of diffusion of CO2 from the body 
and contribute to greater CO2 retention. 
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A portion of all tidal volume (VT) is comprised of alveolar ventilation (Valv) and dead 
space ventilation (Vd). We can define dead space ventilation as the portion of VT that does not 
participate in gas exchanged and can be conceptualized as wasted ventilation. The volume of 
dead space ventilation to alveolar ventilation can be calculated by the equation VT = Vd + Valv. 
From this equation, it can be understood that each normal breath of VT is comprised of both Vd 
and Valv (Intagliata et al., 2020). In a normal healthy individual’s tidal breath, a rough estimate of 
Vd can be determined by using the equation Vd = 2mL/kg of body weight in a healthy adult 
patient and can comprise roughly a third of the VT (Quinn, 2021). In the pediatric population, the 
Vd can reach up to >3mL/kg of body weight, causing the Vd/VT ratio to be even greater (Numa & 
Newth, 1996). In the younger pediatric population, it is even more important to consider dead 
space ventilation at an early age (<1 yr) as the portion of VT is so much greater due to their 
proportionally larger head size. (Numa & Newth, 1996).  In addition, these neonates are 
primarily abdominal breathers and depend on diaphragmic movement rather than expansion of 
the ribs. This leads to the only respiratory compensation a neonate can produce is an increase in 
respiratory rate and not tidal volume (Hall, 1955). 
Physiological dead space is made up of anatomical dead space and alveolar dead space. 
Anatomical dead space includes the nasopharynx, oropharynx, trachea, and bronchi (Intagliata, 
2020). Alveolar dead space is the alveoli that receive ventilation but not perfusion from the 
alveolar capillaries and thus do not participate in gas exchange. There is a greater risk of 
hypercapnia when factors contribute to the increased physiological dead space in the pediatric 
population. Conditions such as malignant hyperthermia, increased carbon dioxide production, 
and increased tissue oxygen consumption can lead to hypercapnia unless CO2 can be excreted 
through respiratory compensation. An increase in PaCO2 can cause an individual to increase their 
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respiratory rate. As long as the Vd/VT ratio is the same by maintaining a similar VT, an 
individual’s minute ventilation as well as dead space ventilation and alveolar ventilation increase 
as the respiratory rate increases.  
In terms of hypercapnia, PaCO2 levels are increased through production of CO2 and 
maintained by elimination through ventilation. Ventilation is composed of volume and rate of 
respirations, which can be measured as total volume moved within a minute, also known as 
minute ventilation. As mentioned before, a portion of the minute ventilation is dead space. The 
greater the amount of dead space, the less efficient each breath is in terms of taking in oxygen 
and eliminating CO2 (Möller et al., 2017). It can be stated that the more dead space involved, the 
less CO2 elimination occurs, and the greater the chance of developing hypercapnia. Following the 
same logic, by removing dead space with high flow rates, CO2 retention can be avoided. 
Otherwise, greater volumes would be necessary to decrease the Vd/VT ratio, which cannot be 
achieved with a HFNC device.  
In terms of hypoxia, the HFNC can provide a set amount of fraction of inspired oxygen 
(FiO2) up to 1.00 while providing high flow rates. By providing a high saturation of oxygen flow 
to a patient’s lungs as well as washing out physiological dead space, hypoxia that is 
nonrefractory to oxygen therapy can be treated (Papazian et al., 2016). The dead space washout 
prevents the rebreathing of CO2 and allows for oxygen rich gas to reach the alveoli and cross into 
the bloodstream.  
The HFNC can also target a temperature of 37C and provide 100% relative humidity. 
High flow devices deliver gas at rates much greater than an individual’s normal inspiratory rate 
(Ramnrarayan & Schibler, 2017). This bypasses the normal heating and humidifying abilities of 
the upper airway as gas moves towards the lungs. Without heat and humidification, the high flow 
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rates of dry air would deplete tissues and secretions of moisture (Fontanari et al., 1996). This 
would lead to irritation as well as thicker secretions, causing additional harm to a patient who 
already requires respiratory support. By heating and humidifying the gas, the bypassed 
anatomical heating and moisturizing effects can be supplemented and provide comfortable 
therapy to the patient. 
The use of HFNC in adults is routinely administered as an intermediate therapy between 
the venturi mask and noninvasive positive pressure ventilation (Kwon, 2020). The use of HFNC 
in pediatrics has gained attention in recent years and has found its way into clinical practice 
primarily for respiratory support in bronchiolitis patients (Milési et al., 2017). In this in vitro 
study, we will examine the effects of flow from a HFNC on mean airway pressure in the 
pediatric population by using a pediatric lung model. 
 
Purpose of the study 
This study aimed to examine the impact of increasing flow through a HFNC device on 
MAP in a pediatric patient by using an in vitro model. It also aimed to compare the effects that 
different commercial HFNC device has on MAP values by testing multiple HFNC on the same 
flow settings. Lastly, we examine the effects that breathing pattern has on MAP values in a 
pediatric in vitro model.  
Research Questions 
Three study questions drive this study: 
1. Does increasing flow through a HFNC device increase MAP? 
2. Do HFNC devices produce significantly different MAP values? 
3. Do simulated breathing patterns differ in their effect on MAP? 




Significance of Study 
 The current study will contribute to our knowledge of how HFNC devices achieve 
increases in MAP through the increase of flow rate in the pediatric population, ages 6-12. 
Moreover, it will provide an understanding of how HFNC devices effect on MAP can vary by 
manufacturers and how MAP values differ during labored breathing patterns in the pediatric 
population.  
  




REVIEW OF LITERATURE 
The review of literature provides background information of multiple aspects of high 
flow nasal cannulas including: flow therapy, positive pressure therapy, mean airway pressure, 
HFNC devices, and HFNC device uses in the adult and pediatric population. The databases used 
to obtain literature included PubMed, Google Scholar, and CINAHL. Key terms were used in the 
search such as high flow nasal cannula, dead space ventilation, positive pressure therapy, high 
flow therapy, low flow therapy, and mean airway pressure. Data from neonatal studies, pediatric 
studies, and adult studies were included for comparative purposes. Studies included in vitro 
studies as well as randomized control studies and meta-analyses. 
Background Information on HFNC 
HFNC therapy is often ordered for patients who are moderately hypoxemic and can 
benefit from a low amount of positive pressure to stent open the airways and alveoli (Kwon, 
2020). Situations where patients can benefit from the use of HFNC include post extubation 
respiratory support, asthma, respiratory distress, and the prevention of intubation (Coletti et al., 
2017). HFNC allows for the delivery of FiO2 of 1.00 at a flow rate up to 60 (L/min) with a 
precise temperature of 37C (Lodeserto, 2018). The benefit of providing a FiO2 of 1.00 assists 
patients who are responsive to oxygen therapy and possess a higher flow demand. This allows an 
escalation of treatment from the venturi mask which can provide higher flows at an exchange for 
lower FiO2, or from a nonrebreather mask (NRB) which can provide high FiO2 at a low flow 
(Ward, 2013). The HFNC also provides an alternative to patients who are unable to tolerate or 
properly fit a continuous positive airway pressure (CPAP) mask and require a low amount of 
positive pressure ventilation (Ward, 2013). One study found that of 620 pediatric subjects that 
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were given HFNC, only two were documented to discontinue therapy due to discomfort (Coletti 
et al., 2017). 
Flow 
The delivery of gas therapy generates a flow rate as it moves through a patient’s airway. 
This flow rate can be felt by a patient as the force of gas pushes against the airways, indicating to 
the patient if sufficient flow is being made. When patients have normal, patent airways, there 
may be a lower need for high flow rates and instead a greater FiO2 to treat hypoxemia, or a 
partial pressure of oxygen (PaO2) in the arteries less than 80 millimeters of mercury (mmHg) 
(Ward, 2012). Low flow rates can be accomplished with devices such as the nasal cannula, 
simple mask, NRB, or a t-piece. An issue with low flow devices is the effect of a patient’s effort 
on atmospheric air entrainment (Lodeserto, 2018). Atmospheric entrainment causes the delivered 
FiO2 from the source to drop below the set value, providing the patient with a variable FiO2 that 
can be any value below an FiO2 of 1.00. 
When patients have a high flow demand, low flow devices are insufficient to meet a 
patient’s needs. In these instances, a blender set up or high flow device is required to meet and 
exceed a patient’s high flow demand to ensure proper ventilatory support (Nishimura, 2016). 
High flow devices include the venturi mask, high flow nasal cannula, noninvasive positive 
pressure devices, and mechanical ventilation. These devices can produce a flow that exceeds a 
patient’s needs even during respiratory distress, when flow and volume demands are increased.  
Positive pressure 
Positive pressure therapy uses an external source to apply positive pressure to a patient’s 
airway or alveoli. Typically, the external source will be a form of gas delivered to the nares or 
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mouth through an external device such as nasal prongs or mask or through an internal device 
such as an artificial airway (Ekhaguere et al., 2019).  
The pressure achieved in the alveoli during gas delivery is known as plateau pressure 
(PPLT). PPLT represents the delivered volume’s effect of pressure upon the alveoli in the absence 
of active gas flow and results in the measurement of static compliance (CLST) of the lung. CLST 
is the amount of volume that can be increased for each unit of pressure. Normal values for CLST 
in a healthy individual without pulmonary issues are approximately 0.1 liter per centimeter of 
water (L/cm H2O). Greater CLST allows for lower PPLT to be achieved for a given delivered 
volume. CLST and PPLT have an indirect relationship. Greater delivered volumes result in greater 
PPLT. Volume and plateau pressure have a direct relationship. The written formula for CLST can 
be seen as CLST =  volume / (PPLT – PEEP). When the formula is rearranged to isolate PPLT, it 
shows as PPLT = ( volume / CLST) + PEEP. Thus, as CLST decreases or  volume increases, PPLT 
increases. 
The maximum pressure achieved in the patient’s airway during gas delivery is known as 
peak airway pressure or peak inspiratory pressure (PIP). PIP is the highest pressure that is 
measured in the airways and is dependent on the patient’s airway resistance (RAW) and the 
amount of flow passing through the airways (Gali & Goyal, 2003). Greater RAW results in greater 
PIP. Greater flow results in greater PIP. Both RAW and flow have a direct relationship with PIP. 
HFNC creates continuous distending pressure to the pharyngeal airway and a small 
degree to the peak end expiratory pressure in the airway. This maintains functional residual 
capacity. In addition, the positive pressure increases the size of the pharyngeal airway and 
decreases airway resistance during inspiration (Ekhaguere et al., 2019). Low levels PEEP can 
also be produced by HFNC, which help in preventing alveolar collapse at end expiration. This 
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improves oxygenation by increasing function residual capacity, improving ventilation-perfusion 
matching, and redistributing extravascular lung water (Gali & Goyal, 2003).   
Mean airway pressure 
As the name suggests, MAP is the average pressure generated over time within the 
airway. In terms of airway ventilation, mean airway pressure has been monitored during both 
noninvasive and invasive mechanical ventilation. However, as long as there is flow moving 
through the airways, a mean airway pressure may also be recorded during ventilation of any sort. 
As mentioned above, the variables such as gas flow, CLST, volume, and RAW impact the pressure 
generated during ventilation.  
Based on the flow rate set, this device should cause a degree of pressure difference 
depending on the set flow rate. One study found that HFNC provides a low amount of upper 
airway distending pressure (Ward, 2012). Other studies have compared the amount of PEEP 
generated with an open and closed mouth model, finding that open mouth models represent a 
severe leak, with a decrease of up to 50% in PEEP (Nielson et al., 2018). The same study found 
that flows greater than 20 L/min can cause a PEEP of greater than 10 cm H2O. These findings 
support that higher flows may have an impact on MAP by creating a greater amount of PEEP.  
Studies have found that the HFNC does impact PEEP in all age populations, with one study 
stating that the flows required to accomplish a PEEP of 6 increases with age (Nielson et al., 
2018). These findings go on to state that to maintain a PEEP of 6 in a small child, flow rates of 
12-20 L/min would be required. Many studies have been performed to focus on the uses of 
HFNC in the adult population as well as the younger end of the spectrum of the pediatric 
population that focuses on neonates and peri neonates. To make matters more difficult, most 
research performed on the middle range of the pediatric population that spans between 6-12 
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years old has very limited research. The absence of scientific literature pertaining to 6–12-year 
old’s leads practitioners to provide treatment based on evidence that has not been thoroughly 
applied to this age range.   
HFNC Devices 
The HFNC systems used to compare pressure results 
include the Vapotherm Precision Flow (Vapotherm, Exeter, 
New Hampshire) (Figure 1), the Optiflow+ OPT942 (Fisher 
& Paykel, Auckland, New Zealand) (Figure 2), and the 
Hudson RCI HFNC (Teleflex, Wayne, Pennsylvania(Figure 
4).  
HFNC in the Adult Population 
In the adult population, the uses of HFNC have been 
investigated for various clinical conditions and respiratory support. It is commonly used for 
community acquired pneumonia except in patients with COPD, who would benefit more from 
non-invasive positive pressure ventilation (NIPPV) (Lodeserto et al., 2018). Compared to 
NIPPV, HFNC allows for effective coughing and expulsion of secretions, the ability to be 
suctioned, as well as provides a more 
comfortable interface. Numerous studies 
have been performed to study HFNC in 
the adult population that compare HFNC 
to NIPPV and convention oxygen therapy 
(Frat et al., 2015; Ni et al., 2017; Azoulay 
et al., 2018). HFNC was compared to 




Figure 1 Vapotherm Precision Flow® 
HFNC System  
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NIPPV and NRB in adult patients with community-acquired pneumonia and found that although 
no significant differences were found in intubation rates, HFNC 
did show improved results in 90-day all-cause mortality compared 
to the NIPPV and NRB (Frat et al., 2015). When compared to 
NIPPV and conventional oxygen therapy, HFNC reduced 
endotracheal intubation rates in patients experiencing acute 
respiratory failure (Ni et al., 2017). Azoulay et al. (2018) 
examined HFNC compared to conventional oxygen therapy in 
immunocompromised subjects and found that HFNC achieved 
improvements in oxygenation. However, HFNC failed to 
demonstrate differences in 28-day mortality, intubation rates, and 
hospital length of stay. Although this study conflicts with the previous studies that included 
NIPPV, it shows that the effect of HFNC can produce different effects based on the presence of 
chronic conditions. 
HFNC in the Pediatric Population 
The age range of pediatric patients span from one year to eighteen years. Our search 
found that the majority of HFNC interventions and comparisons performed in the pediatric 
population surrounded the earlier six years of life.  In particular, HFNC is primarily used to treat 
bronchiolitis in patients two years old and younger (Peterson et al., 2021). The respiratory 
support it provides with high flow and heated, humidified gas has led to a decrease in intubation 
and length of hospital stay in pediatrics younger than two years old. Further, HFNC therapy has 
been successfully utilized in respiratory support to prevent re-intubation (Peterson et al., 2021). 
In a study performed by McKiernan et al. (2009) 9% of infants admitted to the PICU with 
Figure 4 Hudson HFNC 
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bronchiolitis required intubation following the implementation of HFNC therapy.  Prior to the 
implementation of HFNC therapy, intubation rates in the PICU for infants with bronchiolitis was 
23% (McKiernan et al., 2009). The study also found that HFNC helped decrease the respiratory 
rate compared to alternative respiratory support. 
Comparisons between HFNC therapy and nasal continuous positive airway pressure 
(nCPAP) in neonates with bronchiolitis were conducted by Metge et al. (2014) and found no 
differences in the management of severe bronchiolitis between groups. However, this study only 
included a small sample of thirty-four neonates. In a multicentered randomized controlled trial 
comparing HFNC and nCPAP, Milési et al (2017) found that HFNC therapy was not as effective 
as nCPAP in neonates with acute viral bronchiolitis. When respiratory treatment failed with 
HFNC therapy, two-thirds of infants were successfully treated with nCPAP. In terms of tolerance 
between the two devices, HFNC therapy was better tolerated due to a higher degree of comfort 
that allowed for the infant’s unobstructed visual field and unrestricted communication abilities 
(Milési et al., 2017).  
Ramnarayan & Schibler (2017) stated that in the last decade, HFNC therapy in the 
pediatric population has gained popularity. Critically ill children with bronchiolitis, asthma, 
respiratory failure, and neuromuscular illnesses have been managed with HFNC therapy. As the 
indications for more uses of HFNC broadens, it presents the need to better understand how 
HFNC device produce these benefits and if there are risks involved (Sorkness et al., 2019). A 
benefit of HFNC is the amount of pressure it can provide to a patient’s airway, specifically the 
pharyngeal pressure and peak end expiratory pressure (PEEP) (Baudin et al., 2016). The amount 
of pressure found varies between studies. Baudin et al. (2016) reports that a PEEP of 2-7 cm H2O 
can be generated depending on the flow, nasal cannula size, and if the mouth is open or closed. 
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Schmid et al. (2017) sites that at flow rates of 1-6 L/min and open mouth compared to closed 
mouth, the distending pressure does not exceed 2 cm H2O and 10 cm H2O, respectively. 
One of the most important aspects of this research is to provide an association between 
the increase of flow through a HFNC and its impact on MAP since airway pressures cannot be 
monitored using a HFNC system. Although flow rate, FiO2, heat, and humidification can be set 
this high flow system cannot measure the airway pressure like NIPPV and mechanical 
ventilation can, making this unknown pressure potentially hazardous. Some risks identified for 
HFNC include pneumothorax, pneumomediastinum, or clinically important epistaxis. Three 
cases were identified retrospectively where pediatric patients experienced serious air leak 
syndromes related to HFNC therapy. While 2 cases involved a patient less than two-years old, 
the third case involved a 16-year-old male. On a flow rate of 20 L/min, this patient developed 
pneumomediastinum and subcutaneous air leaks. Although other airway pressure therapies were 
implemented, the exact cause of injury includes the effect of flow from the HFNC (Hedge & 
Prodhan, 2013). Chang et al. (2011) found that HFNC devices produce much higher pressures 
compared to a CPAP device at all flow rates ranging from 1 to 8 L/min. CPAP generated 
approximately 30 cm H2O compared to HFNC at greater than 120 cm H2O when set at 8 L/min. 
If these results are accurate, HFNC flows should be examined closely to ensure proper settings 
are chosen for at risk patients. 
This lack of research itself stands as a reason for further research regarding the middle 
pediatric population. This bench study will bridge the gap of knowledge for HFNC therapy 
between adult and the younger pediatric population, as well as ensure that a continuum of 
understanding of HFNC devices exists. 
 




 There is insufficient data on the effects of HFNC in the pediatric population, specifically 
the ages 6-12-years-old. While numerous large-scale studies have been conducted in the neonatal 
population and adult population, the same initiatives have not been taken for the middle pediatric 
population. HFNC can enhance oxygenation provide a small amount of ventilatory support 
through dead space washout. However, the high flows generated are unmeasured during oxygen 
therapy and places patients at an increased risk of barotrauma. For this reason, this study looks to 
evaluate the effects of increasing flow through HFNC devices on MAP in our study population 
to expand our knowledge of flow on pressure gradients. 
 
  





The goal of this study was to observe if pressure gradients were generated by the HFNC 
on a spontaneous breathing pediatric lung model. Three study questions directed the research 
methods: (1) Does greater flow through a high flow nasal cannula increase MAP? (2) Do the 
devices used in this study produce statistically different values? (3) Is greater MAP produced 
during simulated unlabored breathing compared to labored breathing pattern? 
 The focus was to investigate whether or not an increased flow rate would also increase 
the MAP. To simulate a spontaneous breathing patient, a system needed to be constructed to 
provide the negative pressure associated with spontaneous breaths. To do this, a double lung 
model, the Michigan Instruments Labs (MIL) Dual Adult TTL Lung (Michigan Instruments, Inc. 
Grand Rapids, Michigan) was utilized with a board to connect both lungs to move as a single 
unit. Attached to one side of the double lung model would be a ventilator on assist control 
volume control settings to create a negative pressure dynamic on the opposing lung model. The 
ventilator was used in this setting to provide a precise tidal volume, respiratory rate, and time of 
inspiration and expiration. The board that is clamped to both sides of the lung model ensure that 
synchronous movement occurs as the ventilator provides mandatory breaths to Side A. As Side 
A rises due to positive pressure from the ventilator, Side B will also rise due to the clamping of 
the board to both sides of the test and training lung and will therefore generate negative pressure 
inside of Side B. Side B of the double lung model would receive flow from the pediatric HFNC 
circuit.  
The HFNC circuit will provide flow to the lung model through a constructed pair of nares 
model using two 6.0 mm endotracheal tube (Medtronic, Dublin, Ireland) (ETT) trimmed to 
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exclude the cuff and fitted into an 8.5 mm ETT (Medtronic, Dublin, Ireland). This produced an 
upper airway model that consisted of two cuff-less 6.0 mm ETT to be paired together and 
secured within the 8. 5mm ETT. Silicon sealant was used in the space between the two 6.0 mm 
ETT and the 8.5 mm ETT to secure and seal the gaps. The size of the ETT was selected so the 
inner lumen diameter would be the approximate size of the nares of a pediatric patient that we 
used for this study. 
Stands with clamps was positioned to hold the fabricated airway and HFNC device in 
place so the nasal prongs are properly fit within the in vitro nares as seen in Figures 1 and 2. 
Adjustments were made so the clamps did not compress and 
jeopardize the patency of either piece of equipment. An auxiliary 
pressure sensor was attached to the circuit on Side B leading from the 
fabricated airway to the TTL to measure airway pressures as seen in 
Figure 5. For the Hudson RCI and Optiflow HFNC, a high flow 
Thorpe tube (5-75 lpm) was utilized and 
connected to an adaptor to the Fisher and 
Paykel MR290 Auto-fill Chamber and Heated Breathing Tube with 
MicroCell Technology as seen in Figure 6. 
The age range of pediatric patients span from one year to 
eighteen years. For the purposes of this study, we have chosen the 
age range to encompass the middle range of the pediatric population, 
ages 5-12. This age range was chosen based off the study conducted 
by Coletti et al. (2017) that found that the majority of patients that 
were managed with HFNC tended to be < 12 years old. The 
Figure 6 MR290 Auto-fill 
Chamber and Heated 
Breathing Tube with MicroCell 
Technology used to connect 
HFNC devices to high flow 
Thorpe tube 
Figure 5 Auxiliary 
pressure sensor is attached 
between the fabricated 
airway and the TTL 
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distribution between age groups were equal. The Vapotherm guidelines recommend that 
pediatric/adult small HFNC be used for the age range of 6-12 years old. The outer diameter of 
the pediatric/adult small HFNC is 2.7mm and can supply 5-40L/min. Each of the constructed 
nares would have an inner diameter greater than 5.73 mm to simulate the nares of our target 
population. For this study, a size 6.0 mm ETT was used to simulate a single nare, so two 6.0 mm 
ETT were used. 
Lung Model 
The in vitro lung model used for this 
study was the Michigan Instruments Labs 
(MIL) Dual Adult TTL Lung as seen in 
Figure 7. The Dual Adult TTL has two 
independent lungs that allow for independent 
ventilation. Compliance for both sets of lungs 
was set to 0.1 L/cmH2O. No additional 
resistance was included for this study.  
Ventilator 
The Hamilton-G5 ventilator as seen in Figure 8 
(Hamilton Medical, Inc. Reno, Nevada) was utilized for 
this study. Ventilator settings were chosen to mimic 
pediatric ventilation. Two parameters to simulate 
Figure 7 Dual Adult TTL with clamped board 
Figure 8 Hamilton-G5 ventilator 
Note. Side A on the left of the TTL is ventilated 
through the Hamilton-G5. Side B on the right of the 
TTL is receiving flow through the HFNC devices. 
The board clamped across both sides of the TTL 
simulated negative pressure ventilation on Side B. 
 
Note. The Hamilton-G5 ventilator provides 
ventilation to Side A of the TTL and also 
shows pressure reading from the flow 
generated from the HFNC systems on Side 
B. 
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labored and non-labored breathing were used. Non-labored parameters were set as followed: 
tidal volume of 170 mL, respiratory rate of 20, PEEP of 0, FiO2 of 0.21, and flow rate of 20.4 
L/min to produce an I:E ratio of 1:2.8. Labored parameters were set as followed: tidal volume of 
170 mL, respiratory rate of 40, PEEP of 0, FiO2 of 0.21, and flow rate of 40.8 L/min to produce 
an I:E ratio of 1:2.8.  
Tidal volumes were determined by calculating the expected tidal volumes for an average 
height ten-year old pediatric, regardless of gender. According to Bonthuis et al. (2012), the 
average ten-year old is approximately 140 cm. To determine the IBW of a 140 cm child, we used 
the formula provided by Bilharz et al. (2018) as stated: IBW (male) = [(18.41 – 0.096 (age)) + 
(0.00087 (age2))] x (height2). For a 140 cm child, the IBW was calculated to be 34.37 kg. Based 
on the findings from Santschi et al. (2007)97 pediatric intensivists recommended a tidal volume 
of 5mL/kg for a ten-year old. The tidal volume was calculated to be 171.85 mL for a 140 cm 
child. For this study, a tidal volume of 170 mL will be used for ease of controls. Ventilator 
calibration will be performed per manufacturer guidelines prior to testing.  
Data Collection 
Protocols described in Appendix A and Appendix B were used for data collection 
monitored by the Hamilton-G5 ventilator. The PEEP and peak inspiratory pressure (PIP) were 
recorded for this study. Warm-up periods included in the protocols were performed prior to the 
recording of pressures from 20 breaths. 
 MAP was calculated using the recorded PIP and PEEP, as well as the time constants of 
the recorded breaths. By using the formula MAP = [(TI x PIP) + (TE x PEEP)] / TTOT where TI 
represents time of inspiration, TE represents time of expiration, and TTOT represents the total 
cycle time of a complete respiration, we calculated the MAP for all breaths. Under normal 
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breathing conditions, an individual inspires by moving their diaphragm downwards towards their 
pelvis. This causes negative pressure to be produced within the thoracic cavity and within the 
airways. Since we are using an in vitro method in this study, we will be utilizing the Hamilton-
G5 ventilator to produce the breaths that a normal person would create. 
 The Hamilton-G5 ventilator can provide a precise amount of volume, pressure, and flow 
while measuring these values. For the calculation mentioned above that is used to calculate 
MAP, we are unable to identify the TI and TE in a normal spontaneously breathing person. The 
ventilator will therefore be able to produce a measurable and concise amount of flow and 
pressure for the exact time that we set it to. On the Hamilton-G5 ventilator, we can set the TI by 
going into the ventilator settings, clicking on peak flow setting, and adjusting your flow rate. The 
ventilator is capable of calculating the set inspiratory time and expiratory time, as well as the 
ratio of inspiratory time and expiratory time based on the ventilator peak flow rate setting and the 
tidal volume setting. Since the TI and TE are provided to us, we can use those values in the 
calculation for MAP. Using the auxiliary pressure sensor attached from the ventilator to the 
circuit between the fabricated airway and Side B of the test lung, we can obtain the peak airway 
pressure and PEEP in the spontaneous breathing model. The peak airway pressure and PEEP can 
then be used in the calculation to determine true MAP for each breath.  
Data Analysis 
SPSS for Windows (version 26.0) was used to analyze the data. The analysis performed 
on the data included descriptive statistics, two-way ANOVA, and a Bonferroni test. Descriptive 
statistics were used to assess the MAP values amount different flow rates, breathing patterns, and 
HFNC devices. Two-way ANOVA was used to compare differences in MAP values among 
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different flow rates and breathing patterns for different HFNC devices. The Bonferroni 
correction was used for the post-hoc test. A p-value of less than 0.05 was considered significant. 
  





The focus of this study was to determine if the effect of greater flow through a HFNC 
resulted in an increased MAP. In addition, this study was constructed to determine if the pressure 
outputs of the three commercial devices at the designated flow rates were statistically different. 
Finally, this study investigated whether MAP results were different between breathing patterns. 
360 pressure measurements were recorded and calculated for analysis. 20 measurements were 
taken for each grouping of HFNC systems, flow rates, and simulated breathing patterns for a 
total of 18 combinations. Figures 9 and 10 show an upward trend in average MAP across devices 




Figure 9 Device Comparison for average MAP for simulated unlabored breathing pattern 
Note. All comparisons were significantly different. p < 0.001. 








Does increasing flow through a HFNC device increase MAP? 
The first question was addressed by using a two-way ANOVA analysis for each 
simulated breathing pattern and comparing the effects of each flow rate for each HFNC system. 
There was a statistically significant interaction between the effects of HFNC device and flow 
rate, F (4,342) = 22.088, p < 0.05, HFNC device and simulated breathing mode, F (2,342), p < 
0.05, flow rate and breathing mode, F (2,342), p = 0.02, and HFNC, flow rate, and simulated 
breathing mode, F (4,342), p < 0.05. Our post hoc analysis show differences in MAP between 
each flow rate for all three HFNC, p < 0.05. Results can be seen in Table 1. 
Note. All comparisons were significantly different. p < 0.001. 
Figure 10 Device Comparison for average MAP for simulated labored breathing pattern 




Do HFNC devices produce significantly different MAP values? 
The second question was addressed by using a two-way ANOVA analysis for each 
simulated breathing pattern and comparing the effects of each HFNC system at each flow rate. 
There was a statistically significant interaction between the effects of HFNC device and flow 
rate, F (4,342) = 22.088, p < 0.05, HFNC device and simulated breathing mode, F (2,342), p < 
Table 1 2-way ANOVA performed comparing the effects on MAP between all HFNC devices, all flow rates, and 
all breathing patterns 
Running Head: INCREASING FLOW TO HFNC   
 
24 
0.05, flow rate and breathing mode, F (2,342), p = 0.02, and HFNC, flow rate, and simulated 
breathing mode, F (4,342), p < 0.05.  Our post hoc analysis show differences in MAP between 
each device for all three flow rates, p < 0.05. Results can be seen in Table 1. 
Do simulated breathing patterns differ in their effect on MAP? 
The third question was addressed by using an independent T-test for each HFNC system 
at a single flow, compared between unlabored and labored groups. A total of the nine 
independent T-test analyses performed: three for each HFNC system for each of the three flow 
rates. There is a significant difference in MAP between simulated unlabored and labored 
breathing groups for all three HFNC systems at all three flow rates, p < 0.05.  
Summary 
In conclusion, this study was able to answer three questions. Figure 1 shows that as flow 
increased from 10 to 15 to 20 L/min, a greater MAP was produced. For all devices and simulated 
breathing patterns, 20 L/min produced the greatest amount of MAP. Statistical analysis showed a 
significant difference between devices on the amount of MAP produced. In addition, a 
significant difference was found between MAP produced between simulated labored and 
unlabored breathing patterns. The simulated labored breathing pattern on average produced a 
greater amount of MAP than the simulated unlabored breathing pattern. 
 
  





This study was designed to answer three questions. The first question was to determine if 
there were a positive association between greater flow rates through the HFNC and increased 
MAP. The second question was to determine if HFNC devices produced statistically different 
MAP values. The third question was to determine if the average MAP was greater during 
simulated unlabored breathing patterns or simulated labored breathing patterns. This study made 
three separate comparisons within the following variables to determine if they caused a 
significant difference on MAP: flow rates, HFNC devices, and simulated breathing patterns. 
Does increasing flow through a HFNC device increase MAP? 
Using the pediatric in vitro model, 20 PIP recordings were measured using three HFNC 
systems: Vapotherm, Hudson, and Optiflow+. The average recorded MAP produced a value 
greater than 0 cm H2O for all three flow rates. The average MAP rose with each increase in liter 
flow in increments of 5 liters per minute. Therefore, we have found that HFNC increases MAP 
and greater flow through the HFNC produces greater MAP. Since the amount of volume being 
provided by the ventilator was set to 170 mL, the amount of airway pressure would be the 
product of lung compliance and tidal volume. Using the formula of MAP = [(TI x PIP) + (TE x 
PEEP)] / TTOT, we can determine that as PIP increases, MAP increases. Based on the results of 
this study, the greater the flow used through the HFNC, the greater the PIP. Since PIP increased 
with greater flow, it can be concluded that MAP increases with greater flow. 
Nielson et al. (2017) support that HFNC generate PEEP as the flow rate increases and are 
capable of generating a PEEP of 6 cm H2O at a flow rate of 12-20 L/min. This would explain the 
increases in MAP as flow rate increased, since PEEP is part of the equation to calculate MAP. 
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Nielson et al.’s study results differed from this study when comparing measured pressures. They 
claimed that the Vapotherm HFNC produced higher pressures than the Optiflow HFNC, while 
this study showed that Vapotherm produced the lowest pressures. In addition, that study 
concluded that as flow increased, CO2 clearance also increased until a change point was reached 
(Nielson et al. 2017). 
For clinical application, the positive association of increasing the flow through a HFNC 
device to obtain a higher MAP is an intuitive concept. This study contributes to the body of 
knowledge that this concept applies to the pediatric population as well. When working with 
patients, increasing the flow through a HFNC device will produce a greater amount of MAP, 
which has been shown to improve oxygenation status.  
Do HFNC devices produce significantly different MAP values? 
The three HFNC systems were compared at different flow rates for a side-by-side 
comparison. Of the three commercial systems, the Hudson HFNC system produced the highest 
MAP at each flow rate. The greatest MAP produced was at the flow rate of 20 L/min with the 
Hudson HFNC system at 3.83 cm H2O during labored breathing and 3.8 cm H2O during 
unlabored breathing with an average MAP of 3.81 cm H2O and 3.7 cm H2O respectively. The 
Vapotherm HFNC system at the highest flow produced a maximum MAP of 1.78 cm H2O during 
labored breathing and 1.48 cm H2O during unlabored breathing with an average MAP of 1.7 cm 
H2O and 1.5 cm H2O respectively. The Optiflow+ HFNC system at 20 L/min flow produced a 
MAP of 1.96 cm H2O during labored breathing and 1.78 cm H2O during unlabored breathing 
with an average MAP of 2.0 cm H2O and 1.83 cm H2O respectively. Two-way ANOVA showed 
significant differences as liter flow increased. Upon comparison of the three commercial HFNC 
systems, the Hudson produced the greatest MAP at all flows and simulated breathing patterns. 
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Upon further investigation, we measured the nasal prong diameters of each HFNC device 
to determine if there was an indication as to what could cause the MAP differences. Per 
manufacturer recommendations, HFNC prongs should take up no more than 50% of the area of a 
patient’s nare. Using a caliper, we found the outer diameters of the Vapotherm (4.05 mm), 
Hudson (4.93 mm), and Optiflow+ (4.58 mm). When calculating the area each HFNC nasal 
prong occupied, 12.882 mm2, 19.089 mm2, and 16.475 mm2 respectively. When compared to the 
6.0 mm ETT area of 27.274 mm2, we calculated the area percentage of nasal prong displacement 
for the Vapotherm (47.2%), Hudson (70.0%), and Optiflow+ (60.4%). When comparing the 
amount of area displacement to the average MAP values, similar comparisons can be made as the 
Hudson HFNC nasal prongs displaced the largest portion of the 6.0 mm ETT and also produced 
the greatest MAP value while the Vapotherm HFNC nasal prongs displaced the smallest portion 
of the 6.0 mm ETT and produced the lowest MAP value. The Hudson HFNC may have also 
produced the greatest expiratory resistance, contributing to a small degree of end expiratory lung 
recruitment. These findings differ from the study performed by Nielsen et al. (2018) where they 
speculate that smaller bore cannula produced a higher flow velocity. An in vitro study also 
confirmed that increases in leaked flow resulted in decreased pressure readings (Ejiofor et al., 
2019). This supports that smaller nasal prongs allow for larger leaks and decreased pressure 
generation. 
Understanding the different amounts of MAP generated by different devices is a 
consideration that must be accounted for in the clinical setting. If one device produced 
significantly different pressures than another, the clinician should be prepared to adjust the 
devices their facility has in stock in order to achieve the same MAP. Since HFNC systems do not 
provide a pressure measurement, this knowledge is even more crucial to understand (Schmid et 
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al., 2017). This study does not utilize precise flow delivery systems for two devices, as 
mentioned in the limitations. For that reason, a repeated study with proper flow delivery systems 
should be conducted to obtain more accurate results. 
Do simulated breathing patterns differ in their effect on MAP? 
 To determine if breathing patterns impacted MAP, we looked at each HFNC device and 
compared its values against itself at the same flow rate but between breathing patterns. We 
utilized the independent T-test to analyze the results for all HFNC devices at each flow rate. The 
analysis showed significant differences in MAP between simulated unlabored and labored 
breathing groups for all HFNC devices at each flow rate (p < 0.05). The importance of this 
finding is that the efficacy of the HFNC devices during increased respiratory rates. If the MAP 
generated during labored breathing produced decreased values, HFNC devices would not be 
effective in generating increased MAP during tachypneic breathing. In contrast, since the MAP 
generated during simulated labored breathing were greater than during normal unlabored 
breathing, the HFNC devices are more effective during tachypneic episodes.  
 McKiernan et al. (2010) found that infants in respiratory distress showed clear 
improvements in respiratory rate within 90 minutes of HFNC therapy if HFNC were to be 
successful. Infants showed a decrease in RR by 14 breath per minute (bpm) if HFNC was 
effective compared to 1 bpm if therapy was ineffective and required an escalation in therapy. 
This window allows for clinical teams to anticipate effectiveness of therapy quickly and alter 
courses if necessary (McKiernan et al., 2010). 
 Moving forward, understanding the degree of MAP generated during increased 
respiratory rates compared to respiratory rates within normal limits can drive treatment plans. 
Since the MAP is greater during higher respiratory rates, the amount of flow may be decreased if 
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there is a risk of barotrauma with the patient. In addition, if a patient is started on a HFNC device 
during a tachypneic episode, flows can be increased following the episode to maintain the same 
amount of MAP. Dead space washout also normalizes gases, and therefore reduces the drive 
behind the increased work of breathing (Ejiofor et al., 2019). Understanding the dynamics of 
HFNC on MAP during different respiratory rates can explain differences in oxygen saturation 
when HFNC settings are not changed and should be considered when evaluating treatment 
effectiveness. 
Limitations 
There are several limitations evident in this study. The following limitations have been 
identified and considered by the researcher for this study. 
1. In vitro results generalize the potential findings that can be expected in the normal 
population.  
2. The fabricated in vitro model is not physiologically correct. The material used does not 
contain the same characteristics of an actual person’s nasal cavity or airway and can 
produce different values. 
3. The fabricated in vitro model may affect the flow of gas through the airway in a manner 
unlike the normal airway of an actual person. The airway in this study may produce 
greater or less turbulence than in an actual person as this information was not measured 
for comparison. Normal airways converge into a single airway at the oropharynx and 
contain a variety of structures that produce resistance against flow such as the nasal 
turbinates. 
4. The fitting of the HFNC may not have been appropriate for the diameter size of the 
fabricated in vitro model used. Per manufacturer speculations, the diameter of the nasal 
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prongs should not exceed 50% of the nares. For this study, we used a single fabricated in 
vitro model for the nares and chose the HFNC system that were recommended for this 
age group. Different sizes nasal prongs may affect the amount of air entrainment and 
influence the amount of flow and pressure produced by each device. 
5. No humidity was included in this study. Although these HFNC are constructed to 
produce 100% relative humidity, no humidity was included from the patient side or from 
the flow being delivered to the patient. The delivered dry air may produce a different 
flow dynamic than humidified air, and a humidified airway may produce less resistance 
than dry air (Fontanari et al., 1996). 
6. No heat was used in this study. In addition to humidification, no heat was applied from 
the patient side, nor the flow delivered. Dry air delivery may produce a different flow 
dynamic than heated, humidified air, and heated, humidified from the patient side may 
produce greater resistance than dry air. 
7. No flow sensor was utilized. Although flow was set digitally on the Vapotherm HFNC 
system, a high flow Thorpe tube was used to produce flow with the Hudson and 
Optiflow+ HFNC systems. This may produce different values in a repeated study and 
can affect results. 
8. The VT used in this study is based on the average height of a ten-year old child, then 
calculated to determine IBW and multiplied to determine ideal tidal volumes per kg. 
Height for this age group can vary upon gender and beginning of puberty. VT may be 
different compared to other studies if volumes were determined another way. Further, 
during an exacerbation, VT. may be increased or decreased depending on the clinical 
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condition of the patient. Rate was the only variable manipulated to represent a 
tachypneic patient.  
9. The fabricated in vitro model does not consider an open mouth condition. Air 
entrainment and leaks are common when the mouth is open. This study only utilizes a 
nasal airway directly connected to a test lung.  
Need for further research 
Additional research on HFNC systems should be conducted to produce a thorough 
understanding in pediatric patients. Identifying the amount of PEEP that HFNC systems can 
produce with these settings can further the advanced knowledge we have about HFNC in the 
pediatric population. To calculate the PEEP produced in a reproduced study, the researcher can 
measure the MAP in addition to the PIP and subtract the calculated MAP from the actual MAP. 
The difference should be divided by TTOT and divided by TE to obtain the PEEP produced by a 
HFNC system. 
A fabricated model that takes into account an open mouth model may produce additional 
insight. Patients during exacerbations may mouth breathe to achieve greater ventilation and 
inspiratory flow. For these individuals, the calculated MAP will not be accurate or reflect the 
actual pressures generated by the HFNC system. 
A repeated study may consider including humidification and heat to discover if these 
characteristics produce different results. In addition, a flow sensor in the circuit on the HFNC 
systems side can allow for accurate flows to be set for the Hudson and Optiflow+ HFNC 
systems. In addition, taking measurements for the airway without a HFNC system attached 
would provide for a control group to comparison. 
 




HFNC systems are deemed one of the most effective non-invasive oxygenation devices 
available. These systems require quick setup and provide a precise measurement of flow and 
FiO2 that allows for concise care management. The flow delivers gas at a higher rate, applying 
pressure against the airway. During expiration, the continuous flow into the patient’s lungs 
causes resistance to the expiratory flow, producing increased pressure in the airways greater than 
without continuous flow during expiration. This assists in conditions where radial traction is 
decreased, or when secretions in the airways collapse due to the high expiratory flow. Although 
this pressure produced by the HFNC is minimal, it can help in situations where patients require a 
low degree of expiratory airway resistance.  
In addition to precise flow and FiO2, the HFNC systems can provide heat and 
humidification to ensure the delivery of oxygen to a patient is comfortable and humidified. By 
meeting and exceeding the patient’s requirements for oxygenation, flow, heat, and 
humidification, there is a greater tolerance by patients to adhere to treatment. One of the greatest 
obstacles to another highly effective non-invasive oxygenation device, the NIPPV mask, is the 
discomfort that is associated with these masks, ofttimes leading to a discontinuation of therapy 
and worsening conditions. Comfort is certainly an advantage of the HFNC systems, and the 
higher patient tolerance reflects that. 
This study shows that HFNC can produce an increased MAP and PIP as the flow rate is 
increased. As a direct relationship, as flow rate increases, MAP and PIP increase. The 
determination if the increase in PIP is due to the production of PEEP cannot be determined from 
the measurements obtained in this study. As a highly adhered to oxygenation and heated 
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humidification device, the HFNC systems allow for concise care management of patients 
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1. Switch on the power to Hamilton-G5 Ventilator 
2. Run manufacturer flow-sensor calibration 
3. Program ventilator with selected parameters 
a. Respiratory rate of 20 breaths per minute (bpm) 
b. Tidal volume 170mL 
c. Flow of 20.4 L/min 
i. Produces I:E ratio of 1:2.8 
d. Sinusoidal waveform 
e. FiO2 0.21 
f. PEEP of 0 cm H2O 
4. Connect ventilator circuit to positive pressure (side A) of test lung 
a. Lung compliance set at 0.1 L/cm H2O 
5. Activate auxiliary pressure port 
a. Connect auxiliary pressure line to front of ventilator 
b. Connect auxiliary pressure line to adaptor placed in negative airway  
6. Start ventilator and allow to cycle for 1 minute 
7. Start measurement of control with no high flow device at the orifice of the fabricated 
airway 
Vapotherm 
1. Recalibrate Hamilton-G5 flow sensor 
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2. Allow to cycle for 1 minute 
3. Plug Vapotherm unit into wall outlet 
4. Connect Vapotherm unit to oxygen wall outlet and air wall outlet 
5. Switch on the power to Vapotherm unit 
6. Turn flow to 10 L/min on Vapotherm unit 
7. Position Vapotherm cannula with clamp stand so nasal prongs rest inside fabricated 
airway 
8. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
9. Begin recording PIP for 20 breaths (1 minute) 
10. Recalibrate Hamilton-G5 flow sensor 
11. Allow to cycle for 1 minute 
12. Turn flow to 15 L/min on Vapotherm unit 
13. Begin recording PIP for 20 breaths (1 minute) 
14. Recalibrate Hamilton-G5 flow sensor 
15. Allow to cycle for 1 minute 
16. Turn flow to 20 L/min on Vapotherm unit 
17. Begin recording PIP for 20 breaths (1 minute) 
Optiflow+ 
1. Recalibrate Hamilton-G5 flow sensor  
2. Allow to cycle for 1 minute 
3. Connect Optiflow+ unit to high-flow flow meter via oxygen tube adaptor 
4. Turn flow to 10 L/min on high-flow flow meter 
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5. Position Optiflow+ cannula with clamp stand so nasal prongs rest inside fabricated 
airway 
6. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
7. Begin recording PIP for 20 breaths (1 minute) 
8. Recalibrate Hamilton-G5 flow sensor  
9. Allow to cycle for 1 minute 
10. Turn flow to 15 L/min on high-flow flow meter 
11. Begin recording PIP for 20 breaths (1 minute) 
12. Recalibrate Hamilton-G5 flow sensor 
13. Allow to cycle for 1 minute 
14. Turn flow to 20 L/min on high-flow flow meter 
15. Begin recording PIP for 20 breaths (1 minute) 
Hudson 
1. Recalibrate Hamilton-G5 flow sensor 
2. Allow to cycle for 1 minute 
3. Connect Hudson unit to high-flow flow meter via oxygen tube adaptor 
4. Turn flow to 10 L/min on high-flow flow meter 
5. Position Hudson cannula with clamp stand so nasal prongs rest inside fabricated airway 
6. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
7. Begin recording PIP for 20 breaths (1 minute) 
8. Recalibrate Hamilton-G5 flow sensor 
9. Allow to cycle for 1 minute 
10. Turn flow to 15 L/min on high-flow flow meter 
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11. Begin recording PIP for 20 breaths (1 minute) 
12. Recalibrate Hamilton-G5 flow sensor  
13. Allow to cycle for 1 minute 
14. Turn flow to 20 L/min on high-flow flow meter 
15. Begin recording PIP for 20 breaths (1 minute) 
  






1. Switch on the power to Hamilton-G5 Ventilator 
2. Run manufacturer flow-sensor calibration 
3. Program ventilator with selected parameters 
a. Respiratory rate of 40 bpm 
b. Tidal volume 170mL 
c. Flow of 40.8 L/min 
i. Produces I:E ratio of 1:2.8 
d. Sinusoidal waveform 
e. FiO2 0.21 
f. PEEP of 0 cm H2O 
4. Connect ventilator circuit to positive pressure (side A) of test lung 
a. Lung compliance set at 0.1 L/cm H2O 
5. Activate auxiliary pressure port 
a. Connect auxiliary pressure line to front of ventilator 
b. Connect auxiliary pressure line to adaptor placed in negative airway  
6. Start ventilator and allow to cycle for 1 minute 
7. Start measurement of control with no high flow device at the orifice of the fabricated 
airway 
Vapotherm 
1. Recalibrate Hamilton-G5 flow sensor 
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2. Allow to cycle for 1 minute 
3. Plug Vapotherm unit into wall outlet 
4. Connect Vapotherm unit to oxygen wall outlet and air wall outlet 
5. Switch on the power to Vapotherm unit 
6. Turn flow to 10 L/min on Vapotherm unit 
7. Position Vapotherm cannula with clamp stand so nasal prongs rest inside fabricated 
airway 
8. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
9. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
10. Recalibrate Hamilton-G5 flow sensor 
11. Allow to cycle for 1 minute 
12. Turn flow to 15 L/min on Vapotherm unit 
13. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
14. Recalibrate Hamilton-G5 flow sensor 
15. Allow to cycle for 1 minute 
16. Turn flow to 20 L/min on Vapotherm unit 
17. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 




1. Recalibrate Hamilton-G5 flow sensor  
2. Allow to cycle for 1 minute 
3. Connect Optiflow+ unit to high-flow flow meter via oxygen tube adaptor 
4. Turn flow to 10 L/min on high-flow flow meter 
5. Position Optiflow+ cannula with clamp stand so nasal prongs rest inside fabricated 
airway 
6. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
7. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
8. Recalibrate Hamilton-G5 flow sensor  
9. Allow to cycle for 1 minute 
10. Turn flow to 15 L/min on high-flow flow meter 
11. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
12. Recalibrate Hamilton-G5 flow sensor 
13. Allow to cycle for 1 minute 
14. Turn flow to 20 L/min on high-flow flow meter 
15. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 




1. Recalibrate Hamilton-G5 flow sensor 
2. Allow to cycle for 1 minute 
3. Connect Hudson unit to high-flow flow meter via oxygen tube adaptor 
4. Turn flow to 10 L/min on high-flow flow meter 
5. Position Hudson cannula with clamp stand so nasal prongs rest inside fabricated airway 
6. After securing positioning of the nasal prongs, cycle ventilator for 1 minute 
7. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
8. Recalibrate Hamilton-G5 flow sensor 
9. Allow to cycle for 1 minute 
10. Turn flow to 15 L/min on high-flow flow meter 
11. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
12. Recalibrate Hamilton-G5 flow sensor  
13. Allow to cycle for 1 minute 
14. Turn flow to 20 L/min on high-flow flow meter 
15. Begin recording PIP for 20 breaths (1 minute) 
a. Start recording on breath number 2 
b. Record every breath for total of 20 recordings (n=20) 
 
